Submitted: 04 Sep 2022
Accepted: 02 Oct 2022
ePublished: 22 Oct 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Ren Endocrinol. 2022;8: e21062.
doi: 10.34172/jre.2022.21062
  Abstract View: 687
  PDF Download: 353

Original Article

Assessment the efficacy and safety of denosumab use for treatment of osteoporosis in hemodialysis patients

Bassam Al-Helal 1 ORCID logo, Emad Abdallah 1* ORCID logo, Reem Asad 1 ORCID logo, Mohamed Kassab 2, Anas Al Yousef 2, George Nessim 1, Ahmed Radi 2, Mohamed Mostafa 2, Yasser Elsharkawi 1, Esam Allam 1, Ahmed Elmasry 1, Mohamed Hemida 1, Mohamed Abdelgelil 1, Sahar Abdelkareem 1, Mohammad Kamal 1, Amr Saad 1, Shaikha Al-Bader 1, Rania Tharwat 1, Yasser Shaaban 1, Mahmoud Reda 1, Abuhashem Ahmed 1, Nadeen Abdelhaleem 1, Zeinab Zeid 1

1 Al Khezam Dialysis Center, Al-Adan Hospital, Al-Ahmadi City, Kuwait.
2 Nephrology Unit, Farwanya Hospital, Farwanya City, Kuwait.
*Corresponding Author: Corresponding Author: Prof. Emad Abdallah, Email: drabdallah96@gmail.com, , Email: admin@adan-hospital.com


Introduction: Osteoporosis is common in patients with chronic kidney disease (CKD) that could direct to metabolic abnormalities and accelerate bone loss. The administration of bisphosphonates for the management of osteoporosis is contraindicated in cases with severe kidney impairment.

Objectives: In the current investigation, we assess the effectiveness and safety of denosumab administration for the therapy of osteoporosis in hemodialysis (HD) individuals.

Patients and Methods: Seventy-four HD cases with osteoporosis who were received denosumab were assessed retrospectively. All individuals received supplemental vitamin D. Serum calcium, phosphate, parathyroid hormone (PTH), and alkaline phosphatase (ALP) had been measured every three months. Denosumab efficacy was measured by assessing the alterations of bone mineral density (BMD) and plasma ALP.

Results: The mean values of T-score of the spine and hips in HD patients after treatment with denosumab when compared with before treatment was not statistically significant (P=0.7019 and P=0.494 respectively). There was a low mean serum ALP in the HD patients after treatment with denosumab when compared with before treatment, but not statistically significant (P=0.0625). Plasma calcium concentration decreased shortly after the injection of denosumab however returned within fourteen days. Supplementary vitamin D (1.0 to 1.5 μg/day) looked to prevent hypocalcemia and support long treatment with denosumab.

Conclusion: Our study suggests that denosumab is not associated with increases in the BMD of the spine and hip in patients with CKD on HD and hypocalcemia is a concern complication.

Citation: Al-Helal B, Abdallah E, Asad R, Kassab M, Al Yousef A, Nessim G, Radi A, Mostafa M, Elsharkawi Y, Allam E, Elmasry A, Hemida M, Abdelgelil M, Abdelkareem S, Kamal M, Saad A, Al-Bader S, Tharwat R, Shaaban Y, Reda M, Ahmed A, Abdelhaleem N, Zeid Z. Assessment the efficacy and safety of denosumab use for treatment of osteoporosis in hemodialysis patients. J Ren Endocrinol. 2022;8:e21062. doi: 10.34172/jre.2022.21062.
First Name
Last Name
Email Address
Security code

Abstract View: 688

Your browser does not support the canvas element.

PDF Download: 353

Your browser does not support the canvas element.